Assessing InSilico Medicine Cayman TopCo’s Valuation After A 60% 30 Day Share Price Surge

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Setting the stage: what InSilico Medicine Cayman TopCo does and how its shares have moved recently

InSilico Medicine Cayman TopCo (SEHK:3696) has drawn fresh attention after a sharp share price move over the past month, putting its AI driven drug discovery model and current financial profile in focus for investors.

See our latest analysis for InSilico Medicine Cayman TopCo.

The recent 30 day share price return of 60.32% and 7 day share price return of 6.35% suggest momentum has been building, even after a 1 day share price return of negative 4.21% at the latest close of HK$60.25.

If you are looking beyond a single AI biotech name, this could be a good moment to see what is happening across healthcare stocks as another source of ideas.

So with InSilico Medicine Cayman TopCo posting a 60.32% 30 day return, but still reporting HK$53.601 revenue against a HK$44.341 loss, is the surge justified by fundamentals, or is the market already pricing in future growth?

Preferred multiple of price to book: Is it justified?

On the surface, InSilico Medicine Cayman TopCo trades on a P/B ratio of around negative 6.5x, compared with peer levels that sit comfortably in positive territory.

P/B compares a company's market value to its net assets, so when you see a negative figure it usually means liabilities are higher than assets and traditional book based valuation frameworks start to break down. For InSilico Medicine Cayman TopCo, the presence of negative shareholders' equity means that a headline P/B number does not tell you much about how the market is weighing its prospects.

Instead of reading too much into that negative multiple, the key takeaway is that investors are currently pricing this AI based biotech business on factors other than its accounting book value, such as its pipeline potential and technology platform, while the balance sheet still reflects accumulated losses. Compared with both the peer average P/B of 4.8x and the wider Asian Life Sciences industry average of 2.4x, it is clear that book value based yardsticks are not giving a clean valuation signal here.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Preferred multiple of price to book ratio (ABOUT RIGHT as a valuation signal, given negative equity and limited usefulness of P/B here)

However, the story can change quickly if the HK$44.341 loss widens further or if expectations around its AI drug discovery platform cool meaningfully.